Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hod… (NCT00007865) | Clinical Trial Compass
CompletedPhase 2
Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma
United StatesStarted 2000-09-01
Plain-language summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies such as rituximab can locate cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy combined with rituximab in treating patients who have recurrent or refractory non-Hodgkin's lymphoma.
Who can participate
Age range
19 Years – 120 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Histologically confirmed recurrent or refractory B-cell non-Hodgkin's lymphoma
o CD20 positive
* Bidimensionally measurable or evaluable disease
* 19 years old and over
* ECOG 0-2 or Karnofsky 70-100%
* Life expectancy at least 3 months
* WBC at least 3,000/mm3
* Granulocyte count at least 1,000/mm3
* Platelet count at least 100,000/mm3
* Bilirubin no greater than 1.5 times upper limit of normal(ULN)
* AST or ALT no greater than 2.5 times ULN
* Creatinine no greater than 1.5 mg/dL
* Fertile patients must use effective contraception
* Concurrent non-steroidal hormonal therapy allowed for non-disease related conditions (e.g., insulin for diabetes)
Exclusion Criteria:
* No myelodysplastic syndrome or chronic myeloid leukemia
* Not pregnant or nursing/negative pregnancy test
* No other prior malignancy except curatively treated basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the cervix
* No active serious infection
* No other concurrent serious medical condition that would preclude study
* No prior bone marrow or peripheral blood stem cell transplantation for non-Hodgkin's lymphoma
* No other concurrent chemotherapy
* No concurrent corticosteroids except transient administration as antiemetic
* No concurrent radiotherapy
* No other concurrent investigational therapy
* No other concurrent antitumor agents
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.